Bayer vardenafil NDA filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NDA for oral phosphodiesterase inhibitor vardenafil is submitted to FDA Sept. 25. Bayer hopes to launch the erectile dysfunction treatment in the second half of 2002. The firm said at a June Goldman Sachs healthcare conference that it is seeking a marketing partner